CJC-1295 dac 2mg Magnus Pharmaceuticals

CJC-1295 + DAC vs. CJC-1295 without DAC

The term CJC-1295 without DAC is actually an incorrect naming for Modified GRF 1-29. This tetrasubstituted peptide is a modified version of the parent peptide GRF 1-29, known as Sermorelin. Due to the extremely short half-life of the original GRF 1-29, the chemist was able to modify the peptide to obtain a longer biological activity that reduced the metabolic clearance (the amount of blood that is purified per unit of time from a given substance). Although modified Modified GRF 1-29 resulted in greater peptide binding, the average user would still have to apply it 2-3 times a day with GHRP peptides to obtain maximum endogenous growth hormone release efficiency. Adding the drug affinity complex (DAC) to Modified GRF 1-29 (CJC-1295) allowed for better use of smaller growth hormone pulses that, in combination with the GHRP peptide, activate growth hormone stores and release them during day and night. Adding the DAC component allowed the half-life of the peptide to be extended to approximately 1 week, and it also provided for more stable blood levels after injection. The added DAC binds to albumin circulating in the body and is able to spend several days searching for the receptors to which it can bind. So, briefly, if you prefer shorter RH secretion peaks, then the Optimized GRF 1-29 peptide (CJC-1295 without DAC) will be optimal for you.

However, if you prefer a smaller number of injections then the injection of CJC-1295 + DAC 2 to 3 times a week with your daily GHRP peptide injection could be a way to achieve maximal growth hormone release.